These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 19160140)

  • 1. Nadroparine blunts lipopolysaccharide-induced hypothermia and behavioral depression in mice.
    Akyol C; Ozis E; Cakmak A; Akarsu ES; Kuzu MA
    J Invest Surg; 2008; 21(6):311-7. PubMed ID: 19160140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the vasodilatory effect of nadroparin, enoxaparin, dalteparin, and unfractioned heparin in human internal mammary artery.
    Tasatargil A; Ogutman C; Golbasi I; Karasu E; Dalaklioglu S
    J Cardiovasc Pharmacol; 2005 Jun; 45(6):550-4. PubMed ID: 15897782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nadroparine calcium or enoxaparine in acute coronary syndrome patients suffering renal insufficiency: The nadroparin versus enoxaparin (NaVe) study design.
    Gurfinkel EP; Perel C; Pombo G
    Thromb J; 2004 Jun; 2(1):6. PubMed ID: 15186495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the pharmacokinetic profiles of three low molecular mass heparins--dalteparin, enoxaparin and nadroparin--administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism).
    Collignon F; Frydman A; Caplain H; Ozoux ML; Le Roux Y; Bouthier J; Thébault JJ
    Thromb Haemost; 1995 Apr; 73(4):630-40. PubMed ID: 7495071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different effects of enoxaparin, nadroparin, and dalteparin on plasma TFPI during hemodialysis: a prospective crossover randomized study.
    Naumnik B; Rydzewska-Rosołowska A; Myśliwiec M
    Clin Appl Thromb Hemost; 2011 Oct; 17(5):480-6. PubMed ID: 20682597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High plasma endostatin level unaffected by low-molecular weight heparin in hemodialysis patients--a preliminary report.
    Rydzewska-Rosolowska A; Borawski J; Mysliwiec M
    Adv Med Sci; 2009; 54(2):199-202. PubMed ID: 19758969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the effects of unfractionated heparin and the low-molecular-weight heparins dalteparin and enoxaparin on spontaneous platelet aggregation and adenosine diphosphate activity in platelets during the third trimester of pregnancy.
    Ajayi AA; Pharmacols FB; Cooper J; Horn EH; Rubin PC
    Methods Find Exp Clin Pharmacol; 2007 Oct; 29(8):539-45. PubMed ID: 18040530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of heparin and low-molecular-weight heparins on bone mechanical properties in rats.
    Folwarczna J; Janiec W; Sliwiński L
    Thromb Haemost; 2004 Nov; 92(5):940-6. PubMed ID: 15543319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiangiogenic activities of bemiparin sodium, enoxaparin sodium, nadroparin calcium and tinzaparin sodium.
    Dogan OT; Polat ZA; Karahan O; Epozturk K; Altun A; Akkurt I; Cetin A
    Thromb Res; 2011 Oct; 128(4):e29-32. PubMed ID: 21605890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anticoagulation with dalteparin and nadroparin in nocturnal haemodialysis.
    Verhave G; Weijmer MC; van Jaarsveld BC
    Neth J Med; 2015 Jul; 73(6):270-5. PubMed ID: 26228191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel point-of-care assay for the monitoring of low-molecular weight heparins in the cardiac catheterization laboratory.
    Marmur JD; Lakhani M; El Rouby S; Cavusoglu E
    J Invasive Cardiol; 2008 Sep; 20(9):449-54. PubMed ID: 18762674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-molecular weight heparins.
    Talley JD
    J Ark Med Soc; 1997 Apr; 93(11):555-6. PubMed ID: 9114648
    [No Abstract]   [Full Text] [Related]  

  • 13. Effects of nadroparin, enoxaparin, and unfractionated heparin on endogenous formation of factor Xa and IIa and on thrombelastometry profiles in cord versus adult blood.
    Cvirn G; Hoerl G; Tafeit E; Heinl N; Wodrig K; Wagner T; Koestenberger M; Juergens G
    Neonatology; 2011; 100(1):23-31. PubMed ID: 21150227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nadroparin calcium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders.
    Davis R; Faulds D
    Drugs Aging; 1997 Apr; 10(4):299-322. PubMed ID: 9108990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Is there a difference between low-molecular-weight heparins?].
    Eritsland J
    Tidsskr Nor Laegeforen; 2005 Oct; 125(20):2802-3. PubMed ID: 16244685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of low molecular weight heparins and unfractionated heparin on viability of human umbilical vein endothelial cells.
    Guler T; Polat ZA; Yayci E; Atacag T; Cetin A
    Arch Gynecol Obstet; 2013 Feb; 287(2):217-22. PubMed ID: 22987257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low molecular weight heparin (nadroparine) versus oral anticoagulant (acenocoumarol) in the long-term treatment of deep venous thrombosis: comparison of efficacy, safety and hospitalisation period in 105 patients.
    Mazokopakis EE; Vrentzos GE; Ganotakis ES
    Curr Med Res Opin; 2003; 19(6):565-6. PubMed ID: 14594529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thromboprophylaxis following caesarean section--a comparison of the antithrombotic properties of three low molecular weight heparins--dalteparin, enoxaparin and tinzaparin.
    Ellison J; Thomson AJ; Conkie JA; McCall F; Walker D; Greer A
    Thromb Haemost; 2001 Dec; 86(6):1374-8. PubMed ID: 11776302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Bleeding complication due to accumulation of low-molecular-weight heparin in a patient with renal insufficiency].
    Schneiter S; Huynh-Do U; Heizmann M
    Praxis (Bern 1994); 2007 May; 96(18):733-7. PubMed ID: 17520842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of nadroparine on coagulation mechanisms: ultrastructural analysis.
    Sunar H; Hüseyinova G; Canbaz S; Halici U; Duran E
    Blood Coagul Fibrinolysis; 2003 Dec; 14(8):703-6. PubMed ID: 14614347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.